Sunesis Pharmaceuticals to Report Fourth Quarter and Full-Year 2007 Financial Results on March 11, 2008

SOUTH SAN FRANCISCO, Calif., March 5 SunesisPharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceuticalcompany developing novel anticancer therapeutics, today announced thatmanagement will hold an investor conference call on Tuesday, March 11, 2008 at10:30 a.m. ET/7:30 a.m. PT to discuss financial results for the fourth quarterand fiscal year ended December 31, 2007.

Individual and institutional investors can access the call via (877) 604-9668 (U.S. and Canada) or (719) 325-4904 (international). To access the liveaudio webcast or the subsequent archived recording, visit the "Investors andMedia - Calendar of Events" section of the Sunesis website athttp://www.sunesis.com. Please log on to Sunesis' website several minutesprior to the start of the presentation to ensure adequate time for anysoftware download that may be necessary.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on thediscovery, development and commercialization of novel small moleculetherapeutics for oncology and other serious diseases. Sunesis has built abroad product candidate portfolio through internal discovery and in-licensingof novel cancer therapeutics. Sunesis is advancing its product candidatesthrough in-house research and development efforts and strategic collaborationswith leading pharmaceutical and biopharmaceutical companies. For additionalinformation on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SOURCE Sunesis Pharmaceuticals, Inc.

Latest Press Release on General News

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...

A 2017 Hyundai Elantra and 760,000 kilometres of life-saving blood donation deliveries

Mr. Tim German's 2017 Hyundai Elantra a.k.a. "Dark Angel," was bought new from Steele Hyundai Halifax and now has more than 760,000 kilometres on the odometer. With his Elantra, Mr....

Philips Respironics Reaches Agreement with US Government on a Consent Decree Creating a Clear Path Forward

April 10, 2024 Philips confirms that further to communicating the main terms of the Philips Respironics consent decree on January 29, 2024, Philips’ subsidiaries Philips Holding USA ...